The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NLG-0301: An open-label, randomized phase 2B active control study of second-line tergenpumatucel-L immunotherapy versus docetaxel in patients with progressive or relapsed non-small cell lung cancer (NSCLC).
Ramaswamy Govindan
No relevant relationships to disclose
John Charles Morris
No relevant relationships to disclose
Gabriela R. Rossi
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Nicholas N. Vahanian
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Charles J. Link
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics